Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             201 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 106 A breathlessness aid – simple helpful hints for patients Davies, C.
 2012
 75 S1 p. S35-
1 p.
 artikel
2 161 Acute toxicity of prophylactic cranial irradiation (PCI) in extensive stage small cell lung cancer (ES-SCLC): A prospective audit from a UK radiotherapy centre Chan, C.
 2012
 75 S1 p. S53-
1 p.
 artikel
3 75 Addressing the lung cancer research agenda through user partnership working: the Stepping Stones experience Noble, S.
 2012
 75 S1 p. S25-
1 p.
 artikel
4 34 Adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC): the West of Scotland Experience Slater, S.
 2012
 75 S1 p. S11-
1 p.
 artikel
5 77 Analysis of the effectiveness of written clinical communication about lung cancer patients at St James's Institute of Oncology, Leeds McMillan, C.
 2012
 75 S1 p. S26-
1 p.
 artikel
6 20 An audit of docetaxel for 2nd line treatment of patients with advanced non small cell lung cancer (NSCLC): toxicities and outcomes in NHS Tayside 2005–2010 Capaldi, S.
 2012
 75 S1 p. S7-
1 p.
 artikel
7 197 An audit of pulmonary functions tests before radical lung cancer surgery Robertson, A.
 2012
 75 S1 p. S64-S65
2 p.
 artikel
8 169 An audit of small cell lung cancer (SCLC) outcomes and the rates of neutropenic sepsis in Poole 2009–2010 Gorf, L.
 2012
 75 S1 p. S56-
1 p.
 artikel
9 151 An audit on 90-day post-radiation therapy mortality rate in lung cancer Ong, E.
 2012
 75 S1 p. S49-S50
2 p.
 artikel
10 88 A network's experience of using data to benchmark and improve 1-year survival rates in lung cancer Lok, S.
 2012
 75 S1 p. S29-S30
2 p.
 artikel
11 129 Anterior mediastinal schwannoma Stavroulias, D.
 2012
 75 S1 p. S42-
1 p.
 artikel
12 58 Antibody independent micro-filtration biochip for the diagnosis of lung cancer Tay, A.
 2012
 75 S1 p. S19-
1 p.
 artikel
13 101 A patient story – one man's lung cancer journey Davies, C.
 2012
 75 S1 p. S33-S34
2 p.
 artikel
14 83 A pilot trial of a solitary pulmonary nodule virtual clinic Sutton, B.
 2012
 75 S1 p. S28-
1 p.
 artikel
15 174 A retrospective audit of the clinical management of extensive stage small cell lung cancer in Northern Ireland Forde, C.
 2012
 75 S1 p. S57-
1 p.
 artikel
16 175 A retrospective audit of the clinical management of limited stage small cell lung cancer in Northern Ireland Hussain, A.
 2012
 75 S1 p. S57-S58
2 p.
 artikel
17 51 Are video-assisted thoracoscopic (VATS) pleural biopsies better than open pleural biopsies for diagnosing malignancy? Zaher, S.
 2012
 75 S1 p. S17-
1 p.
 artikel
18 153 A review of concurrent chemoradiotherapy using cisplatin and oral vinorelbine in patients with non-small cell lung cancer (NCSLC) at the Kent Oncology Centre Baldry, C.
 2012
 75 S1 p. S50-
1 p.
 artikel
19 92 A review of follow-up of lung cancer patients treated with surgical resection in a UK teaching hospital Cheyne, L.
 2012
 75 S1 p. S31-
1 p.
 artikel
20 15 A single centre experience of EGFR testing in squamous cell carcinoma of the lung and successful use of gefitinib in a patient with EGFR sensitising exon 19 mutation Walter, H.
 2012
 75 S1 p. S5-S6
2 p.
 artikel
21 53 Assessment of performance status in lung cancer Do oncologists and respiratory physicians agree? Addy, C.
 2012
 75 S1 p. S17-S18
2 p.
 artikel
22 96 A survey of patient attitudes to attending a lung cancer nurse specialist (LCNS) follow up clinic Howison, H.
 2012
 75 S1 p. S32-
1 p.
 artikel
23 188 Audit into outcomes of bronchial stent insertion in lung cancer patients Coote, J.
 2012
 75 S1 p. S62-
1 p.
 artikel
24 26 Audit of efficacy and tolerability of fortnightly oral vinorelbine in patients with advanced NSCLC Garlick, C.
 2012
 75 S1 p. S8-S9
2 p.
 artikel
25 47 Audit of medical thoracoscopy at North Tyneside General Hospital McBrearty, C.
 2012
 75 S1 p. S16-
1 p.
 artikel
26 62 Audit of patients receiving cisplatin/pemetrexed chemotherapy for malignant mesothelioma in NHS Tayside 2005–2010 Cockburn, A.
 2012
 75 S1 p. S21-
1 p.
 artikel
27 40 Audit of patients undergoing bronchoscopy or CT guided biopsy Holland, L.
 2012
 75 S1 p. S13-
1 p.
 artikel
28 125 Audit of prophylactic antibiotics in patients with lung cancer on chemotherapy Doyle, C.
 2012
 75 S1 p. S41-
1 p.
 artikel
29 14 Audit of the management of epithelial growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients within the Kent Oncology Centre and its associated units Biondo, A.
 2012
 75 S1 p. S5-
1 p.
 artikel
30 Author Index 2012
 75 S1 p. S67-S72
6 p.
 artikel
31 61 A year's experience of pleural mesothelioma patients at a tertiary cancer centre Dutton, H.
 2012
 75 S1 p. S20-
1 p.
 artikel
32 46 Benign ultrasound appearances of intra-thoracic lymph nodes during endobronchial ultrasound (EBUS) bronchoscopy predicts benign aetiology Evison, M.
 2012
 75 S1 p. S15-
1 p.
 artikel
33 172 Best practice in small cell lung cancer: Are we meeting national guidance? A 3 year audit of treatment and outcomes in Bournemouth, Dorset, UK Keay, N.
 2012
 75 S1 p. S57-
1 p.
 artikel
34 121 Bronchopulmonary carcinoid tumours: a retrospective analysis of 60 patients King, M.
 2012
 75 S1 p. S40-
1 p.
 artikel
35 67 Can HDAC expression be used to stratify mesothelioma patients for appropriate treatment regimens? Baird, A.-M.
 2012
 75 S1 p. S22-
1 p.
 artikel
36 192 Can the thoracoscore and revised cardiac risk index predict outcomes? Abdelaziz, M.
 2012
 75 S1 p. S63-
1 p.
 artikel
37 120 Carcinoid tumour characteristics, treatment and outcome: results from the National Lung Cancer Audit 2005–2010 Musial, N.
 2012
 75 S1 p. S39-S40
2 p.
 artikel
38 139 Cause of death following radical radiotherapy for non-small cell lung cancer O'Rourke, N.
 2012
 75 S1 p. S45-
1 p.
 artikel
39 63 Chemotherapy for malignant mesothelioma and response assessment by modified RECIST criteria, the St James's Hospital, Dublin experience O'Flaherty, J.
 2012
 75 S1 p. S21-
1 p.
 artikel
40 18 Chemotherapy or tyrosine kinase inhibitor for second line treatment in advanced non small cell lung cancer Jyoti, B.
 2012
 75 S1 p. S6-
1 p.
 artikel
41 1 Chronic exposure to TNF-α and IL-1β increases the invasive potential of a human bronchial epithelial cell line Baird, A.-M.
 2012
 75 S1 p. S1-
1 p.
 artikel
42 9 Circulating tumour cells in non-small cell lung cancer, isolation and subset analysis using VitaAssay modified invasion assay O'Flaherty, J.
 2012
 75 S1 p. S3-S4
2 p.
 artikel
43 164 Clinical characteristics and radiotherapy planning parameters as predictors of radiation-induced oesophageal toxicity following radical radiotherapy (rRT) for small cell (SCLC) and non-small cell lung cancer (NSCLC) Helbrow, J.
 2012
 75 S1 p. S54-
1 p.
 artikel
44 165 Clinical characteristics and radiotherapy planning parameters as predictors of radiation-induced pulmonary toxicity following radical radiotherapy (rRT) for small cell (SCLC) and non-small cell lung cancer (NSCLC) Helbrow, J.
 2012
 75 S1 p. S54-
1 p.
 artikel
45 152 Clinical prediction for acute toxicity in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiation Uyterlinde, W.
 2012
 75 S1 p. S50-
1 p.
 artikel
46 124 Clostridium difficile infection does not cause higher mortality in oncology patients Morgan, C.
 2012
 75 S1 p. S41-
1 p.
 artikel
47 23 Comparison of gemcitabine-carboplatin and oral vinorelbine-carboplatin in patients with advanced non-small cell lung cancer Mitchell, C.
 2012
 75 S1 p. S8-
1 p.
 artikel
48 190 Completing the audit cycle improves surgical standards in lung cancer Hagan, M.
 2012
 75 S1 p. S62-
1 p.
 artikel
49 176 Concurrent chemoradiation for lung cancer in routine practice Rooney, K.
 2012
 75 S1 p. S58-
1 p.
 artikel
50 154 Concurrent chemoradiotherapy (cCTRT) for locally-advanced, unresectable non-small cell lung cancer (LA-NSCLC): A national survey of current practice Helbrow, J.
 2012
 75 S1 p. S50-S51
2 p.
 artikel
51 145 Continuous hyperfractionated accelerated radiotherapy in non-small cell lung cancer: the West of Scotland experience Nowicki, S.
 2012
 75 S1 p. S47-
1 p.
 artikel
52 167 CONVERT: Concurrent ONce-daily VErsus twice-daily RadioTherapy. A phase III randomised controlled trial for patients with limited stage small cell lung cancer (LS-SCLC) and good performance status Faivre-Finn, C.
 2012
 75 S1 p. S55-
1 p.
 artikel
53 105 Coordinating care and management of lung cancer patients undergoing concurrent chemotherapy and radiotherapy Gardener, T.
 2012
 75 S1 p. S35-
1 p.
 artikel
54 22 Costs of cisplatin and carboplatin in combination with gemcitabine in advanced non-small cell lung cancer: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients Gaunt, P.
 2012
 75 S1 p. S7-
1 p.
 artikel
55 71 Cross-system consistency of the National Lung Cancer Audit and SCTS Thoracic Surgery Database in a single cancer network Begum, S.
 2012
 75 S1 p. S23-S24
2 p.
 artikel
56 132 Depression in COPD and lung cancer: determining the contributing risk factor Md Yusof, M.Y.
 2012
 75 S1 p. S43-
1 p.
 artikel
57 93 Developing a model of care for survivorship in lung cancer Stent, G.
 2012
 75 S1 p. S31-
1 p.
 artikel
58 98 Developing a nurse led pulmonary nodule surveillance service Thompson, J.
 2012
 75 S1 p. S33-
1 p.
 artikel
59 43 Development of a bronchoscopy briefing and checklist Hidelaratchi, M.D.P.
 2012
 75 S1 p. S14-S15
2 p.
 artikel
60 6 Distribution profile of baseline gene expression to standardise tumour expression: a pilot study of cisplatin resistant genes in lung cancer Freidin, M.
 2012
 75 S1 p. S2-S3
2 p.
 artikel
61 182 Do circulating tumour cell (CTC) counts correlate with tumour volume in limited disease small cell lung cancer (LD-SCLC)? An exploratory clinical study with survival outcomes Koh, P.
 2012
 75 S1 p. S60-
1 p.
 artikel
62 37 Does T staging on PET/CT correlate with pathological size of specimen in resected lung cancer? Teo, B.
 2012
 75 S1 p. S12-
1 p.
 artikel
63 94 Do we still need doctors for lung cancer follow up Stent, G.
 2012
 75 S1 p. S31-S32
2 p.
 artikel
64 73 Downgrading red flag referrals for lung cancer Harkness, H.
 2012
 75 S1 p. S24-S25
2 p.
 artikel
65 52 Early diagnosis of lung cancer initiative in North East Essex Lawson, M.
 2012
 75 S1 p. S17-
1 p.
 artikel
66 Editorial Board 2012
 75 S1 p. i-
1 p.
 artikel
67 155 Effect of radiation dose in consolidation radiotherapy for advanced/metastatic non small cell lung cancer Eldeeb, H.
 2012
 75 S1 p. S51-
1 p.
 artikel
68 163 Efficacy of prophylactic cranial irradiation in small cell lung cancer, subsequent management of brain metastases McLaughlin, L.
 2012
 75 S1 p. S53-S54
2 p.
 artikel
69 50 Efficacy of thoracoscopic pleurodesis: 2 years experience at a district general hospital Malhotra, P.
 2012
 75 S1 p. S16-S17
2 p.
 artikel
70 12 EGFR mutational testing in non-squamous lung cancer: 12 months experience from a Cancer Unit in UK Bulusu, V.
 2012
 75 S1 p. S4-S5
2 p.
 artikel
71 13 EGFR-mutation analysis, treatment and outcomes in newly diagnosed patients with non-small cell lung cancer (NSCLC): a single-institution retrospective review Enting, D.
 2012
 75 S1 p. S5-
1 p.
 artikel
72 143 Elderly non small cell lung cancer patients benefit from CHART – results of audit from a CHART centre Walker, G.
 2012
 75 S1 p. S46-S47
2 p.
 artikel
73 187 Endobronchial intervention at Oxford – two year experience and outcomes Rehman, S.
 2012
 75 S1 p. S61-
1 p.
 artikel
74 19 Erlotinib in the treatment of non-small-cell lung cancer Kyte, J.
 2012
 75 S1 p. S6-S7
2 p.
 artikel
75 117 Establishing a mesothelioma support group Slade, G.
 2012
 75 S1 p. S38-
1 p.
 artikel
76 82 Establishing a virtual chemotherapy clinic from a regional cardiothoracic centre Gilligan, D.
 2012
 75 S1 p. S27-S28
2 p.
 artikel
77 48 Evaluation of the safety and efficacy of a medical thoracoscopy service in a UK District General Hospital Blaxill, P.
 2012
 75 S1 p. S16-
1 p.
 artikel
78 168 Experiences of pre-trial quality assurance (QA) for the CONVERT trial. A multicentre randomised phase III trial for good performance status patients with limited stage small cell lung cancer Wilson, E.
 2012
 75 S1 p. S55-S56
2 p.
 artikel
79 95 Expert nurse consensus on the follow-up and management of patients receiving erlotinib for the treatment of non-small-cell lung cancer McPhelim, J.
 2012
 75 S1 p. S32-
1 p.
 artikel
80 140 FDG positron emission tomography maximum standardised uptake value (SUVmax) has prognostic value in non-small cell lung cancer treated with radical radiotherapy Button, M.
 2012
 75 S1 p. S46-
1 p.
 artikel
81 173 Follow-up after first line treatment for extensive stage small cell lung cancer – another postcode lottery? Moss, C.
 2012
 75 S1 p. S57-
1 p.
 artikel
82 91 Follow-up of patients with advanced NSCLC following 1st line chemotherapy. A British Thoracic Oncology Group national survey Darlison, L.
 2012
 75 S1 p. S30-S31
2 p.
 artikel
83 78 ‘Garbage in, garbage out’ – assessing the quality of new patient histories by thoracic oncologists Forde, C.
 2012
 75 S1 p. S26-
1 p.
 artikel
84 183 Has VATS segmentectomy come of age? Mazza, F.
 2012
 75 S1 p. S60-
1 p.
 artikel
85 5 High content analysis (HCA) assay for the quantification and localisation of activated HER2 and EGFR Edwards, C.
 2012
 75 S1 p. S2-
1 p.
 artikel
86 102 Holistic needs assessment – what the patient doesn't tell us Roberts, J.
 2012
 75 S1 p. S34-
1 p.
 artikel
87 107 Hyponatraemia in oncology: magnitude of the problem: proposed management algorithm for syndrome of anti diuretic hormone associated with cancer: a joint acute oncology & acute medicine project Bulusu, V.
 2012
 75 S1 p. S35-
1 p.
 artikel
88 2 IL-23A is epigenetically regulated in non small cell lung cancer Baird, A.-M.
 2012
 75 S1 p. S1-
1 p.
 artikel
89 136 Implications of smoking for quality of life and medical decision making in lung cancer patients Rowland, C.
 2012
 75 S1 p. S44-S45
2 p.
 artikel
90 141 Improvements in radical radiotherapy outcomes for early NSCLC in Northern Ireland O'Hare, J.
 2012
 75 S1 p. S46-
1 p.
 artikel
91 97 Improving outcomes for palliative lung cancer patients: experience of a multiprofessional parallel clinic model in a district general hospital Smith, J.
 2012
 75 S1 p. S32-
1 p.
 artikel
92 170 Improving small cell carcinoma treatment in Liverpool McIver, A.
 2012
 75 S1 p. S56-
1 p.
 artikel
93 119 Improving the care of patients with mesothelioma: development of an online educational resource for health care professionals Darlison, L.
 2012
 75 S1 p. S39-
1 p.
 artikel
94 56 Infrared spectral signatures of respiratory carcinogenesis: a pilot study Brown, J.
 2012
 75 S1 p. S18-S19
2 p.
 artikel
95 66 Inhibition of EGFR, MTOR and COX2 pathways in mesothelioma cells Agarwal, V.
 2012
 75 S1 p. S22-
1 p.
 artikel
96 115 Inter hospital communication, fast, reliable, patient centred information exchange McPhelim, J.
 2012
 75 S1 p. S38-
1 p.
 artikel
97 189 Intra-operative lymph node assessment in lung cancer resection Knight, K.
 2012
 75 S1 p. S62-
1 p.
 artikel
98 84 Investigating and managing patients with pleural disease within an ambulatory care setting to prevent hospital admissions Hodgson, L.
 2012
 75 S1 p. S28-
1 p.
 artikel
99 130 Is chronic obstructive pulmonary disease an independent risk factor for lung cancer? Powell, H.
 2012
 75 S1 p. S42-
1 p.
 artikel
100 109 Lung cancer and mesothelioma: the journeys end? An analysis of end of life data for patients diagnosed with a lung cancer or mesothelioma in 2009 Summerfield, S.
 2012
 75 S1 p. S36-
1 p.
 artikel
101 81 Lung cancer audit at East and North Hertfordshire NHS Trust – comparison with national results and impact of service developments over 2008–2010 Potter, V.A.
 2012
 75 S1 p. S27-
1 p.
 artikel
102 70 Lung Cancer in patients older than 75 years – referral pathways, interventions & outcomes: experience from a cancer unit Jeffs, Y.
 2012
 75 S1 p. S23-
1 p.
 artikel
103 41 Lung cancer mimics and significant incidental findings in patients undergoing fast track pre-clinic computed tomography Hobbins, S.
 2012
 75 S1 p. S13-S14
2 p.
 artikel
104 193 Lung cancer resection can be performed safely following previous contralateral pneumonectomy Gupta, P.
 2012
 75 S1 p. S63-
1 p.
 artikel
105 194 Lung resections in octogenarians: 7 year experience in a single centre Kenny, L.
 2012
 75 S1 p. S63-S64
2 p.
 artikel
106 64 Macrophage stimulating protein (MSP) up-regulates the Src kinases in malignant pleural mesothelioma Baird, A.-M.
 2012
 75 S1 p. S21-
1 p.
 artikel
107 89 Management of stage III non-small-cell lung cancer (NSCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN): an analysis of current practice Alves, A.
 2012
 75 S1 p. S30-
1 p.
 artikel
108 127 Management of thymic tumours – single centre study Latif, M.
 2012
 75 S1 p. S41-S42
2 p.
 artikel
109 104 Managing the care of patients receiving concurrent chemo-radiotherapy for non-small cell lung cancer an overview Halkyard, E.
 2012
 75 S1 p. S34-S35
2 p.
 artikel
110 116 Measuring the workload and effectiveness of the lung cancer nurse specialist Bowles, K.
 2012
 75 S1 p. S38-
1 p.
 artikel
111 198 Measuring TLCO prior to referral for surgical resection of lung cancer: are we following current guidance? Stolagiewicz, N.
 2012
 75 S1 p. S65-
1 p.
 artikel
112 157 Mortality rates after palliative radiotherapy for lung cancer from a single UK radiotherapy centre Gupta, K.
 2012
 75 S1 p. S51-S52
2 p.
 artikel
113 110 Motivations of palliative lung cancer patients to participate in a non-placebo clinical trial (QualFRAG) Edwards, M.
 2012
 75 S1 p. S36-
1 p.
 artikel
114 7 NFkB–IκBα interaction: a mechanism of resistance to cisplatin in NSCLC Heavey, S.
 2012
 75 S1 p. S3-
1 p.
 artikel
115 114 NHS Lanarkshire lung cancer nursing team: patient referral guidelines Irvine, L.
 2012
 75 S1 p. S37-S38
2 p.
 artikel
116 149 Novel immobilisation technique implemented for use in the treatment of SABR using VMAT Moore, K.
 2012
 75 S1 p. S49-
1 p.
 artikel
117 36 Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer Tai, F.W.D.
 2012
 75 S1 p. S12-
1 p.
 artikel
118 146 One year on: early report of intensity modulated radiotherapy (IMRT) for locally advanced lung cancer at the Christie Robinson, H.
 2012
 75 S1 p. S48-
1 p.
 artikel
119 128 Outcome in excised thymomas: role of prognostic factors and impact of additional malignancies on survival Granato, F.
 2012
 75 S1 p. S42-
1 p.
 artikel
120 162 Outcomes following prophylactic cranial irradiation (PCI) in extensive small cell lung cancer (ESCLC) delivered in NHS Tayside Armstrong, S.
 2012
 75 S1 p. S53-
1 p.
 artikel
121 25 Outcomes of cisplatin plus pemetrexed as first-line therapy for adenocarcinoma and large cell carcinoma of the lung how an oncological centre in Tayside, Scotland compares with the literature Buchanan, G.
 2012
 75 S1 p. S8-
1 p.
 artikel
122 171 Outcomes of small cell lung cancer; data from a District General Hospital (DGH) in the North-West England Gudur, S.
 2012
 75 S1 p. S56-
1 p.
 artikel
123 29 Palliative chemotherapy with carboplatin and oral vinorelbine in advanced non-small cell lung cancer (NSCLC) – A single centre pilot audit Garikipati, S.
 2012
 75 S1 p. S9-S10
2 p.
 artikel
124 133 Patient experience data collection in the improving lung cancer outcomes project: one year on Jimenez, S.
 2012
 75 S1 p. S43-S44
2 p.
 artikel
125 195 Patient's experiences of a pre and post surgery rehabilitation programme for lung cancer (Rehabilitation Of lung Cancer (ROC) programme): a qualitative interview study Parsons, A.
 2012
 75 S1 p. S64-
1 p.
 artikel
126 69 PIT: A phase III trial of prophylactic irradiation of tracks in patients with malignant pleural mesothelioma following invasive chest wall intervention Bayman, N.
 2012
 75 S1 p. S23-
1 p.
 artikel
127 68 Preserving the lung during radical surgery for mesothelioma: quality of life, spirometry and lung volume measurements Socci, L.
 2012
 75 S1 p. S22-S23
2 p.
 artikel
128 138 Pre-SOCCAR pilot study of concurrent chemoradiation using 55 Gy in 20 fractions with cisplatinum and vinorelbine in stage III NSCLC Maguire, J.
 2012
 75 S1 p. S45-
1 p.
 artikel
129 39 Prevalence of supraclavicular lymph node metastases in N2 and N3 lung cancer using CT and PET/CT Clay, C.
 2012
 75 S1 p. S13-
1 p.
 artikel
130 158 Prophylactic cranial irradiation in lung cancer: a single institution experience Naidoo, J.
 2012
 75 S1 p. S52-
1 p.
 artikel
131 45 Proposed quality measures and quality indicators for providing an endobronchial ultrasound (EBUS) bronchoscopy service Evison, M.
 2012
 75 S1 p. S15-
1 p.
 artikel
132 144 Prospective data of continuous hyperfractionated accelerated radiotherapy (CHART): does performance status have an impact on radiation acute toxicities and resources? Pickles, R.
 2012
 75 S1 p. S47-
1 p.
 artikel
133 137 Prospective quality of life measurement in SOCCAR no disadvantage for patients receiving concurrent vs sequential treatment with 55Gy/20f and cisplatinum/vinorelbine Maguire, J.
 2012
 75 S1 p. S45-
1 p.
 artikel
134 54 PS score discordance and why it matters May, C.H.
 2012
 75 S1 p. S18-
1 p.
 artikel
135 199 Pulmonary vein circulating tumour cells from patients undergoing curative resection of non-small cell lung cancer Crosbie, P.
 2012
 75 S1 p. S65-
1 p.
 artikel
136 49 Qualitative and quantitative experience of Medical Thoracoscopy (MT) in a DGH Khan, B.
 2012
 75 S1 p. S16-
1 p.
 artikel
137 147 Quality of life after stereotactic body radiotherapy (SBRT) for early NSCLC in medically inoperable patients: preliminary analysis Morgan, L.
 2012
 75 S1 p. S48-S49
2 p.
 artikel
138 159 Quality of life after treatment for brain metastases: An update on the QUARTZ trial – one year on from an interim data release Mulvenna, P.
 2012
 75 S1 p. S52-
1 p.
 artikel
139 191 Quality of lung cancer surgery: analysis of potential outcome measures across a cancer network Sharkey, A.
 2012
 75 S1 p. S62-S63
2 p.
 artikel
140 85 Radical treatment rates for early stage lung cancer Brown, A.
 2012
 75 S1 p. S28-S29
2 p.
 artikel
141 108 Raising the awareness of percutaneous cervical cordotomy as an aid to pain relief for patients with unilateral chest pain caused by thoracic malignancy Beaty, D.
 2012
 75 S1 p. S35-S36
2 p.
 artikel
142 24 Re-audit of use of pemetrexed/cisplatin for non-squamous non-small-cell lung cancer in Northern Ireland McDermott, R.
 2012
 75 S1 p. S8-
1 p.
 artikel
143 122 Recurrent endotracheal and laryngeal metastasis of primary squamous cell lung carcinoma: A case report Ling, Y.
 2012
 75 S1 p. S40-
1 p.
 artikel
144 28 Re-design of day case cisplatin/vinorelbine administration for adjuvant treatment of patients with non-small cell lung cancer MacLean, F.
 2012
 75 S1 p. S9-
1 p.
 artikel
145 90 Retrospective audit of radically treated non-small cell lung cancer (NSCLC) patients at the St James's Institute of Oncology (SJIO), Leeds Teaching Hospital NHS Trust (LTHT) Franks, K.
 2012
 75 S1 p. S30-
1 p.
 artikel
146 10 RNA from FFPE tissue is suitable for exon array analysis if extracted utilizing a robust protocol which incorporates laser capture microdissection Brown, L.
 2012
 75 S1 p. S4-
1 p.
 artikel
147 35 Safety and tolerability of adjuvant platinum and vinorelbine chemotherapy in completely resected early stage non small cell lung cancer patients – single centre review Gyi, M.M.
 2012
 75 S1 p. S11-S12
2 p.
 artikel
148 32 Second line chemotherapy in NSCLC: Middlesbrough cancer centre audit Iqbal, S.
 2012
 75 S1 p. S10-S11
2 p.
 artikel
149 80 Service improvement and impact on the East and North Hertfordshire NHS Trust lung cancer service Potter, V.A.
 2012
 75 S1 p. S27-
1 p.
 artikel
150 72 Service improvement through the ILCOP methodology: successes and failures after 1 year Beckett, P.
 2012
 75 S1 p. S24-
1 p.
 artikel
151 150 Setting up a SABR service using VMAT in a busy clinical department Muirhead, R.
 2012
 75 S1 p. S49-
1 p.
 artikel
152 177 Single institution experience in management of small cell lung cancer (SCLC) in Mid-Western Ireland Quintyne, K.I.
 2012
 75 S1 p. S58-
1 p.
 artikel
153 135 Smoking and lung cancer in women Powell, H.
 2012
 75 S1 p. S44-
1 p.
 artikel
154 134 Smoking attitudes among cancer centre staff Parkins, G.
 2012
 75 S1 p. S44-
1 p.
 artikel
155 86 Social deprivation does not affect lung cancer stage, survival or management – a population study of Leeds patients 2008–2010 Cheyne, L.
 2012
 75 S1 p. S29-
1 p.
 artikel
156 57 Squamous cell and adenocarcinoma ‘lineage’ markers in large cell carcinoma of the lung Kerr, K.M.
 2012
 75 S1 p. S19-
1 p.
 artikel
157 38 Staging the brain in non-small cell lung cancer (NSCLC) – has NICE gone far enough? Khan, E.
 2012
 75 S1 p. S12-S13
2 p.
 artikel
158 79 Standards of lung cancer management in two different hospitals in a single trust Montefort, M.
 2012
 75 S1 p. S26-S27
2 p.
 artikel
159 65 Steroid receptor coactivators in malignant pleural mesothelioma: expression and prognostic value Jennings, C.J.
 2012
 75 S1 p. S21-S22
2 p.
 artikel
160 55 Suitability of EBUS-TBNA specimens for the subtyping and genotyping of non-small cell lung cancer: a multi-centre pragmatic implementation study of 774 patients Brown, J.
 2012
 75 S1 p. S18-
1 p.
 artikel
161 131 Symptoms with which patients with lung cancer present predict outcomes Athey, V.
 2012
 75 S1 p. S43-
1 p.
 artikel
162 31 Systemic therapy in the elderly: A network audit of non small cell lung cancer patients Das, T.S.
 2012
 75 S1 p. S10-
1 p.
 artikel
163 60 The changing face of mesothelioma diagnosis: A ten-year review of practice in Leicester, UK Sutton, B.
 2012
 75 S1 p. S20-
1 p.
 artikel
164 103 The clinical and psychosocial impact of antiangiogenic and EGFR inhibitors as anti-cancer treatments Magee, L.
 2012
 75 S1 p. S34-
1 p.
 artikel
165 74 The Colchester fast-track chest X-ray referral pathway Harris, J.
 2012
 75 S1 p. S25-
1 p.
 artikel
166 112 The comprehensive lung cancer nursing service Creech, L.
 2012
 75 S1 p. S37-
1 p.
 artikel
167 113 The development of lung cancer nursing documentation: An integral part of patient care Irvine, L.
 2012
 75 S1 p. S37-
1 p.
 artikel
168 8 The effects of PI3K/Akt/mTOR pathway inhibitors on a panel of NSCLC cell lines Heavey, S.
 2012
 75 S1 p. S3-
1 p.
 artikel
169 3 The establishment of an isogenic model of cisplatin resistance and the identification of a potential microRNA signature in non-small cell lung cancer Barr, M.
 2012
 75 S1 p. S1-S2
2 p.
 artikel
170 44 The first 100 endobronchial ultrasound transbronchial needle aspirations at Aberdeen Royal Infirmary Mahendra, P.
 2012
 75 S1 p. S15-
1 p.
 artikel
171 111 The gold standard framework acute hospital pilot and its impact on lung cancer services Thompson, J.
 2012
 75 S1 p. S36-S37
2 p.
 artikel
172 160 The impact of age and performance status on outcome of brain metastases in non-small cell lung cancer (NSCLC) Larbi, E.
 2012
 75 S1 p. S52-
1 p.
 artikel
173 30 The impact of alternative dosing regimens on overall survival (OS) in the treatment of non small cell lung cancer (NSCLC) with Erlotinib Pembroke, C.
 2012
 75 S1 p. S10-
1 p.
 artikel
174 156 The I-START trial: ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer Lester, J.F.
 2012
 75 S1 p. S51-
1 p.
 artikel
175 100 The meaning and significance of routine follow-up in lung cancer: A qualitative study of patient's experiences and the development and evaluation of a new model of follow-up care Sandeman, G.
 2012
 75 S1 p. S33-
1 p.
 artikel
176 178 The National Lung Cancer Audit (NLCA) does not accurately record chemotherapy administration for patients with small cell lung cancer (SCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN) Rudraiah, M.G.
 2012
 75 S1 p. S58-S59
2 p.
 artikel
177 196 The PulMiCC (Pulmonary Metastasectomy in Colorectal Cancer) trial Treasure, T.
 2012
 75 S1 p. S64-
1 p.
 artikel
178 185 The role of explorative thoracotomy in the management of non-small cell lung cancer Rigby, J.
 2012
 75 S1 p. S61-
1 p.
 artikel
179 118 The role of the lung cancer nurse specialist in providing legal advice to patients diagnosed with malignant pleural mesothelioma Bolton, S.
 2012
 75 S1 p. S39-
1 p.
 artikel
180 76 The UK ‘two week rule’ for lung cancer – 5-year survival update Myerson, J.
 2012
 75 S1 p. S25-S26
2 p.
 artikel
181 59 The use of immunohistochemistry in sub-typing non-small cell lung cancer (NSCLC) and reducing the rate of NSCLC not otherwise specified (NSCLC NOS) Skehan, N.
 2012
 75 S1 p. S19-S20
2 p.
 artikel
182 42 The value of fibre-optic bronchoscopy in patients with haemoptysis and non-diagnostic CT scans Leahy, A.
 2012
 75 S1 p. S14-
1 p.
 artikel
183 166 Thoracic radiotherapy in extensive-disease small cell lung cancer: a retrospective review Wilson, J.M.
 2012
 75 S1 p. S55-
1 p.
 artikel
184 181 Tolvaptan use in a patient with metastatic small cell lung cancer Mumby, C.
 2012
 75 S1 p. S59-S60
2 p.
 artikel
185 11 UDP-glucuronosyltransferase polymorphisms and lung cancer risk: a review Potter, V.A.
 2012
 75 S1 p. S4-
1 p.
 artikel
186 123 Unusual presentation of metastases of unknown primary to the mediastinum with long-term survival: case report Eldeeb, H.
 2012
 75 S1 p. S40-
1 p.
 artikel
187 16 Use of gefitinib in the management of patients with advanced non-small cell lung cancer: all Wales experience Scott, G.
 2012
 75 S1 p. S6-
1 p.
 artikel
188 17 Use of Gefitinib (Iressa) in patients with EGFR positive NSCLC in the Pan Birmingham Cancer Network Plant, R.
 2012
 75 S1 p. S6-
1 p.
 artikel
189 33 Use of 2nd line chemotherapy in patients who had received standard platinum based chemotherapy for stage IIIb/IV non-small-cell lung cancer between January 2007 and March 2010 Irvine, L.
 2012
 75 S1 p. S11-
1 p.
 artikel
190 142 Validation of the MAASTRO clinic cancer prediction tool for overall survival following radical NSCLC radiotherapy Young, L.
 2012
 75 S1 p. S46-
1 p.
 artikel
191 4 Vascular endothelial growth factor (VEGF) is an autocrine survival factor in non-small cell lung cancer Barr, M.
 2012
 75 S1 p. S2-
1 p.
 artikel
192 184 VATS lobectomy facilitates delivery of adjuvant chemotherapy following NSCLC resection Abah, U.
 2012
 75 S1 p. S60-S61
2 p.
 artikel
193 27 Venous complications with intravenous vinorelbine: time to move to oral? Jessop, S.
 2012
 75 S1 p. S9-
1 p.
 artikel
194 21 Weekly paclitaxel and three weekly docetaxel appear active and well-tolerated in third and fourth-line advanced NSCLC patients Pender, A.
 2012
 75 S1 p. S7-
1 p.
 artikel
195 179 Why are patients with small cell lung cancer (SCLC) not given chemotherapy? Khan, M.I.
 2012
 75 S1 p. S59-
1 p.
 artikel
196 186 Why does operability for lung cancer vary across trusts within Northern Ireland? Smith, S.
 2012
 75 S1 p. S61-
1 p.
 artikel
197 180 Why do some patients with small cell lung cancer (SCLC) not get chemotherapy? Mackean, M.
 2012
 75 S1 p. S59-
1 p.
 artikel
198 126 Why so blue? Jayaram, A.
 2012
 75 S1 p. S41-
1 p.
 artikel
199 87 Workload of lung cancer MDTs is not associated with outcome Beckett, P.
 2012
 75 S1 p. S29-
1 p.
 artikel
200 99 Would streamlining clinics increase CNS contact for patients with suspected lung cancer? Lamonby, V.
 2012
 75 S1 p. S33-
1 p.
 artikel
201 148 2 year results of lung stereotactic body radiotherapy (SBRT) for medically inoperable peripheral stage I NSCLC at the St James's Institute of Oncology, Leeds Ramasamy, S.
 2012
 75 S1 p. S49-
1 p.
 artikel
                             201 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland